Why These Two Verticals, First

Houston sits at the intersection of both verticals CiteHQ.io was built around, in a way few other cities do. It's home to the Texas Medical Center — one of the largest concentrations of medical innovation anywhere in the world — and it's simultaneously the center of $800 billion in Latin American trade and more than 500,000 Spanish-speaking businesses. That scale isn't static, either: Houston's economy has grown at an average annual rate of 5.1% over the past four years, consistently outpacing the national rate. This is a city still building momentum, not one that already peaked. Most agencies pick a city because that's where they happen to be based. CiteHQ.io is built here because Houston is genuinely where both focus areas converge in one place, at real scale, moving in the right direction.

This is explicitly framed as an initial focus market — a launch-phase choice expected to expand as the business grows beyond ramp-up, not a permanent limitation.

CiteHQ.io focuses on establishing relationships with early-stage medtech and biotech ventures — a focus that started with OmniStem, a physician-supervised regenerative medicine center, which became the proof of concept for the company itself. But the deeper qualification behind this focus area isn't a claim of technical expertise in medicine or in how AI systems work. It's the same pattern recognition that took a first-time mobile operator to profitability against a state monopoly, and that watched, firsthand, which companies survived the dot-com correction and which didn't.

Early-stage founders — especially technical ones — are constantly being pitched by agencies that don't actually understand the difference between creating real value and creating pretense. David spent 1999 to 2005 inside Lucent Technologies during the exact years the telecom industry rebuilt itself around Internet Protocol, then held P&L responsibility for a $100 million-plus business through the correction that followed. That's a specific, verifiable qualification for reading the current AI wave correctly — not a generic claim.

What David brings to early-stage ventures specifically is three perspectives under one hat, not one. As a corporate operator, he led through an infrastructure buildout and the correction that followed it, inside a Fortune 500 company. As a technology venture-builder, he founded and scaled companies from zero, one at a time, with his own capital and reputation on the line. And from building B2C businesses that lived or died on individual consumer trust, he understands what it actually takes to earn belief from a real person — not just win a corporate contract. Early-stage ventures run at a pace and with a resource constraint that punishes generic advice: they need deliverables that work now, not frameworks that would work eventually. That combination of perspectives is built for exactly that reality.

An early-stage founder rarely has to convince just one kind of audience — they have to be understood, in sequence, by investors deciding whether to fund the idea, corporate buyers deciding whether to say yes to it, and individual consumers deciding whether to actually trust and use it. Across two decades and every venture in this record, David has stood on more than one side of that chain — as the operator investors and corporate partners had to be convinced by, and as the entrepreneur building the offer an individual consumer had to trust enough to choose. That fluency was built across the United States and across Latin America at once, in two genuinely integrated languages and cultures, not one market translated into the other after the fact. It is the same full chain — investor, corporate buyer, consumer — that an early-stage venture has to navigate today, and it's why CiteHQ.io is built to help a founder position their brand favorably in front of these three distinct profiles.

Every competitor CiteHQ.io was benchmarked against in early research splits cleanly into two models: agencies based entirely in Latin America, or larger US agencies reaching multiple markets through separate local teams. Nobody runs one integrated team across both sides of the language and border line. CiteHQ.io does — and every service is priced to reflect that as genuine scope, not a translation add-on: native-quality Spanish is the default on everything delivered, not a premium tier.

This isn't a claimed capability. It's a proven one. Long before CiteHQ.io existed, David built and led a prepaid mobile virtual network operator across 10 US markets built specifically for the Hispanic community, and separately built a 10-store retail distribution network serving the same audience — two distinct, revenue-generating ventures built around bilingual, bicultural trust rather than treating it as a secondary market the way national carriers did.

This direction is more than a capability — it's a deliberate positioning. CiteHQ.io is establishing itself directly in Latin America, leveraging two decades of regional relationships built across telecom, banking, and mobile money in Colombia, Costa Rica, and the broader region — the same network documented in Building Things That Didn't Exist Yet. OmniStem, based in the Dominican Republic, is the first live example: CiteHQ.io's work makes it visible and credible to the US-based investors, physicians, and patients who research it before ever making contact.